These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38963127)

  • 1. Novel measures of cognition and function for the AD spectrum in the Novel Measures for Alzheimer's Disease Prevention Trials (NoMAD) project: Psychometric properties, convergent validation, and contrasts with established measures.
    Kim H; Lee S; Levine A; Huber B; Andrews H; Kerner NA; Cohen D; Carlson S; Bell SA; Rivera AM; Gordon ML; Simoes S; Devanand DP; Brickman AM; Schneider LS; Harvey PD; Goldberg TE
    Alzheimers Dement; 2024 Aug; 20(8):5089-5101. PubMed ID: 38963127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel measures for Alzheimer's disease prevention trials (NoMAD).
    Bell SA; Cohen HR; Lee S; Kim H; Ciarleglio A; Andrews H; Rivera AM; Igwe K; Brickman AM; Devanand DP; Harvey PD; Schneider LS; Goldberg TE
    Contemp Clin Trials; 2021 Jul; 106():106425. PubMed ID: 33933666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel approaches to measuring neurocognitive functions in Alzheimer's disease clinical trials.
    Carlson S; Kim H; Devanand DP; Goldberg TE
    Curr Opin Neurol; 2022 Apr; 35(2):240-248. PubMed ID: 35175975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population.
    McDougall F; Edgar C; Mertes M; Delmar P; Fontoura P; Abi-Saab D; Lansdall CJ; Boada M; Doody R
    J Prev Alzheimers Dis; 2021; 8(2):151-160. PubMed ID: 33569561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.
    Wilcock D; Jicha G; Blacker D; Albert MS; D'Orazio LM; Elahi FM; Fornage M; Hinman JD; Knoefel J; Kramer J; Kryscio RJ; Lamar M; Moghekar A; Prestopnik J; Ringman JM; Rosenberg G; Sagare A; Satizabal CL; Schneider J; Seshadri S; Sur S; Tracy RP; Yasar S; Williams V; Singh H; Mazina L; Helmer KG; Corriveau RA; Schwab K; Kivisäkk P; Greenberg SM;
    Alzheimers Dement; 2021 Apr; 17(4):704-715. PubMed ID: 33480172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of Individual and Composite Test Scores from the Cogstate Brief Battery to Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease.
    White JP; Schembri A; Prenn-Gologranc C; Ondrus M; Katina S; Novak P; Lim YY; Edgar C; Maruff P
    J Alzheimers Dis; 2023; 96(4):1781-1799. PubMed ID: 38007647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study.
    Harrison JE; Rentz DM; Brashear HR; Arrighi HM; Ropacki MT; Liu E
    J Prev Alzheimers Dis; 2018; 5(4):236-244. PubMed ID: 30298182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-report instruments of cognitive failures as screening tools for Subjective Cognitive Impairment in older adults.
    Papaliagkas V; Papantoniou G; Tsolaki M; Moraitou D
    Hell J Nucl Med; 2017; 20 Suppl():58-70. PubMed ID: 29324915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a Remote and Fully Automated Story Recall Task to Assess for Early Cognitive Impairment in Older Adults: Longitudinal Case-Control Observational Study.
    Skirrow C; Meszaros M; Meepegama U; Lenain R; Papp KV; Weston J; Fristed E
    JMIR Aging; 2022 Sep; 5(3):e37090. PubMed ID: 36178715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the European Cross-Cultural Neuropsychological Test Battery (CNTB) for the assessment of mild cognitive impairment due to Alzheimer's disease and Parkinson's disease.
    Delgado-Álvarez A; Nielsen TR; Delgado-Alonso C; Valles-Salgado M; López-Carbonero JI; García-Ramos R; Gil-Moreno MJ; Díez-Cirarda M; Matías-Guiu J; Matias-Guiu JA
    Front Aging Neurosci; 2023; 15():1134111. PubMed ID: 37213535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Cognitive Composite for Preclinical Alzheimer's Disease in Korean Older Adults.
    Kim M; Yi D; Byun MS; Ahn H; Jung JH; Kong N; Chang Y; Choi H; Choi J; Kim K; Jung G; Lee DY;
    J Alzheimers Dis; 2023; 96(2):633-641. PubMed ID: 37807780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
    Sampson EL; Jenagaratnam L; McShane R
    Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a real-world simulated instrument for evaluating visuospatial working memory: a preliminary psychometric study on older adults.
    Mirchi Z; Kheirkhah MT; Khosrowabadi R; Fadardi JS; Ramezani M
    BMC Geriatr; 2024 Jun; 24(1):548. PubMed ID: 38914947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Souvenaid for Alzheimer's disease.
    Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
    Sampson EL; Jenagaratnam L; McShane R
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005380. PubMed ID: 24563468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TOMMORROW neuropsychological battery: German language validation and normative study.
    Romero HR; Monsch AU; Hayden KM; Plassman BL; Atkins AS; Keefe RSE; Brewster S; Chiang C; O'Neil J; Runyan G; Atkinson MJ; Crawford S; Budur K; Burns DK; Welsh-Bohmer KA
    Alzheimers Dement (N Y); 2018; 4():314-323. PubMed ID: 30094331
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.